MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
The aim of the study was to evaluate MIC1/GDF15 as a biomarker in the monitoring of bone metastases occurrence.



The assessed group included patients diagnosed with: prostate cancer, breast cancer, lung cancer and colorectal cancer. Patients were divided into two groups based on the scintigraphy of the occurrence of bone metastases. Group 0 contained 55 patients without bone metastases, that served as the control group. Group 1 contained 75 patients with bone metastases.



Higher levels (p<0.0001) of MIC1/GDF15 were found in group 1 (with bone metastases) compared to the group 0. Receiver operating characteristic (ROC) analysis showed an area under the curve (AUC) 0.87. At the point of 90% specificity we found a 65% sensitivity and cut-off value of 1.48 ng/ml.



Circulating MIC1/GDF15 is a powerful biomarker for bone metastatic disease but insufficient sensitivity calls for further studies incorporating combinations with other novel or routine markers.
Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
Jindra
J
Windrichova
Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
Radka
R
Fuchsova
Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic kucerar@fnplzen.cz.
Radek
R
Kucera
Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
Ondrej
O
Topolcan
Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.|Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
Ondrej
O
Fiala
Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
Jindrich
J
Finek
Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
Dagmar
D
Slipkova
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001859:Bone Neoplasms / Q000378:metabolism* / Q000556:secondary*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000378:metabolism / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D055436:Growth Differentiation Factor 15 / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology; D012372:ROC Curve; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; C526140:GDF15 protein, human; D055436:Growth Differentiation Factor 15
MIC1/GDF15; biomarkers; bone metastasis; cancer; scintigraphy